TNX 224

Drug Profile

TNX 224

Alternative Names: 166-32; Anti-factor D monoclonal antibody

Latest Information Update: 15 Dec 2004

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tanox
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Complement factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Reperfusion injury

Most Recent Events

  • 14 Dec 2004 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
  • 27 Jan 2003 TNX 224 is available for licensing [www.tanox.com]
  • 28 Aug 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top